Back to AZNCFView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA12/9/2020
Trixeo Aerosphere
Trixeo Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
propranololPhase 3
Migraine Without Aura
Quetiapine SRPhase 3
Anxiety Disorders
Ceftaroline fosamilPhase 3
Infections
Erlotinib 150/100 mgPhase 3
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Ticagrelor orodispersible tabletsPhase 3
ST Elevation Myocardial Infarction
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts